On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Mersana Therapeutics (United States)

InstitutionResearch output, impact & collaborations

Mersana Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Mersana Therapeutics (United States)?

ScholarIQrecord summary

Mersana Therapeutics (United States) is a research organisation in Cambridge, US. OpenAlex records 149 works and 15,271 citations for it. 74 researchers list it as their most recent affiliation.

How many works does Mersana Therapeutics (United States) have?

ScholarIQindexed works

Mersana Therapeutics (United States) has 149 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Mersana Therapeutics (United States) →

How many citations does Mersana Therapeutics (United States) have?

ScholarIQcitation count

Mersana Therapeutics (United States) has 15,271 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Mersana Therapeutics (United States) →

How many researchers are at Mersana Therapeutics (United States)?

ScholarIQresearcher count

Mersana Therapeutics (United States) has 74 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Mersana Therapeutics (United States)?

ScholarIQavg h-index

Mersana Therapeutics (United States) has an average h-index of 61 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Mersana Therapeutics (United States)?

ScholarIQror

The ROR for Mersana Therapeutics (United States) is on the source record.

Open the ROR →

What is the OpenAlex record for Mersana Therapeutics (United States)?

ScholarIQopenalex

The OpenAlex for Mersana Therapeutics (United States) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Mersana Therapeutics (United States)?

ScholarIQtop researchers by citations

Robert A. Burger · Ovarian cancer diagnosis and treatment

330 works23,028 citations

What are the most-cited papers on Mersana Therapeutics (United States)?

ScholarIQmost cited works

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel, Helen Huang, Rebecca N. Baergen, Shashikant Lele, Larry J. Copeland, Joan L. Walker, Robert A. Burger

New England Journal of Medicine. 20062,636 CitationsOPEN ACCESS

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang

New England Journal of Medicine. 20112,398 CitationsOPEN ACCESS

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel L. Clarke‐Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca N. Baergen

Journal of Clinical Oncology. 20032,059 Citations

Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

Robert A. Burger, Michael W. Sill, Bradley J. Monk, Benjamin E. Greer, Joel I. Sorosky

Journal of Clinical Oncology. 2007884 CitationsOPEN ACCESS

Inherited Mutations in Women With Ovarian Carcinoma

Barbara M. Norquist, Maria I. Harrell, Mark F. Brady, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Yi Qian, Robert A. Burger, John K. Chan, Susan A. Davidson, Robert S. Mannel, Paul DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Elizabeth M. Swisher, Michael J. Birrer

JAMA Oncology. 2015771 CitationsOPEN ACCESS

How much of the research on Mersana Therapeutics (United States) is open access?

ScholarIQopen access share

75%OPEN ACCESS

Gold

Green

25%

Hybrid

Bronze

50%

Closed

25%